Asymptomatic excessive coumarin anticoagulation is a risk factor for thrombotic and bleeding complications of oral anticoagulant therapy

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 8, 2003, Pages 1840-1841

  Poli, D ^a   Antonucci, E ^a   Gensini, G F ^a   Abbrate, R ^a   Prisco, D ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN; COUMARIN DERIVATIVE; PHYTOMENADIONE; WARFARIN;

FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RISK; THROMBOSIS; TIME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; COUMARINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; RISK; THROMBOSIS; TIME FACTORS; VITAMIN K 1; WARFARIN;

EID: 2142640754     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00321.x     Document Type: Letter

References (5)

1. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001; 119: 22s-38s.
2. Italian Federation of Anticoagulation Clinics. A guide to oral anti coagulant therapy. Haemostasis 1998; 28: 1-46.
3. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S, on behalf of the ISCOAT (Italian Study on Complication of Oral Anti coagulant Therapy) Study group. Bleeding complications of oral anti coagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
4. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Raemost 1993; 69: 236-9.
5. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.